{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T11:28:49Z","timestamp":1773746929409,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T00:00:00Z","timestamp":1616716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Magnesium is an essential element that is involved in critical metabolic pathways. A diet deficient in magnesium is associated with an increased risk of developing cancer. Few studies have reported whether a serum magnesium level below the reference range (RR) is associated with prognosis in patients with diffuse large B cell lymphoma (DLBCL). Using a retrospective approach in DLBCL patients undergoing autologous stem cell transplant (AHSCT), we evaluated the association of hypomagnesemia with survival. Totally, 581 patients eligible for AHSCT with a serum magnesium level during the immediate pre-transplant period were identified and 14.1% (82\/581) had hypomagnesemia. Hypomagnesemia was associated with an inferior event-free (EFS) and overall survival (OS) compared to patients with a serum magnesium level within RR; median EFS: 3.9 years (95% CI: 1.63\u20138.98 years) versus 6.29 years (95% CI: 4.73\u20138.95 years) with HR 1.63 (95% CI: 1.09\u20132.43, <jats:italic>p<\/jats:italic>\u2009=\u20090.017) for EFS, and median OS: 7.3 years (95% CI: 2.91\u2014upper limit not estimable) versus 9.7 years (95% CI: 6.92\u201312.3 years) with HR 1.90 (95% CI: 1.22\u20132.96, <jats:italic>p<\/jats:italic>\u2009=\u20090.005) for OS months 0\u201312, respectively. These findings suggest a potentially actionable prognostic factor for patients with DLBCL undergoing AHSCT.<\/jats:p>","DOI":"10.1038\/s41408-021-00452-0","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T15:03:13Z","timestamp":1616770993000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Hypomagnesemia at the time of autologous stem cell transplantation for patients with diffuse large B-cell lymphoma is associated with an increased risk of failure"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6972-7986","authenticated-orcid":false,"given":"Jennifer J.","family":"Gile","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4516-8088","authenticated-orcid":false,"given":"Camden L.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gordon J.","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew A.","family":"Hathcock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jithma P.","family":"Abeykoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joy R.","family":"Heimgartner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikola A.","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Molly","family":"McMahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana N.","family":"Micallef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose C. Villasboas","family":"Bisneto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis F.","family":"Porrata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7350-5531","authenticated-orcid":false,"given":"Jonas","family":"Paludo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen M.","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-6500","authenticated-orcid":false,"given":"Thomas E.","family":"Witzig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,26]]},"reference":[{"key":"452_CR1","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1600-0609.1997.tb00982.x","volume":"59","author":"A Salar","year":"1997","unstructured":"Salar, A. et al. Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases. Eur. J. Haematol. 59, 231\u2013237 (1997).","journal-title":"Eur. J. Haematol."},{"key":"452_CR2","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann, T. M. et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J. Clin. Oncol. 24, 3121\u20133127 (2006).","journal-title":"J. Clin. Oncol."},{"key":"452_CR3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1182\/asheducation-2016.1.366","volume":"2016","author":"B Coiffier","year":"2016","unstructured":"Coiffier, B. & Sarkozy, C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol. Am. Soc. Hematol. Educ. Program 2016, 366\u2013378 (2016).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"452_CR4","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","volume":"32","author":"MJ Maurer","year":"2014","unstructured":"Maurer, M. J. et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J. Clin. Oncol. 32, 1066\u20131073 (2014).","journal-title":"J. Clin. Oncol."},{"key":"452_CR5","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1111\/bjh.15412","volume":"182","author":"C Gisselbrecht","year":"2018","unstructured":"Gisselbrecht, C. & Van Den Neste, E. How I manage patients with relapsed\/refractory diffuse large B cell lymphoma. Br. J. Haematol. 182, 633\u2013643 (2018).","journal-title":"Br. J. Haematol."},{"key":"452_CR6","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","volume":"55","author":"E Gonz\u00e1lez-Barca","year":"2020","unstructured":"Gonz\u00e1lez-Barca, E. et al. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transpl. 55, 393\u2013399 (2020).","journal-title":"Bone Marrow Transpl."},{"key":"452_CR7","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","volume":"333","author":"T Philip","year":"1995","unstructured":"Philip, T. et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma. N. Engl. J. Med. 333, 1540\u20131545 (1995).","journal-title":"N. Engl. J. Med."},{"key":"452_CR8","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1002\/ajh.23524","volume":"88","author":"SJ Nagle","year":"2013","unstructured":"Nagle, S. J. et al. Outcomes of patients with relapsed\/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era. Am. J. Hematol. 88, 890\u2013894 (2013).","journal-title":"Am. J. Hematol."},{"key":"452_CR9","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1182\/blood.V80.8.2142.2142","volume":"80","author":"JM Vose","year":"1992","unstructured":"Vose, J. M. et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up. Blood 80, 2142\u20132148 (1992).","journal-title":"Blood"},{"key":"452_CR10","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bbmt.2008.04.013","volume":"14","author":"LF Porrata","year":"2008","unstructured":"Porrata, L. F. et al. Early lymphocyte recovery predicts superior survival after autologous stem cell transplantation in non-Hodgkin lymphoma: a prospective study. Biol. Blood Marrow Transpl. 14, 807\u2013816 (2008).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"452_CR11","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.bmt.1703236","volume":"28","author":"LF Porrata","year":"2001","unstructured":"Porrata, L. F., Ingle, J. N., Litzow, M. R., Geyer, S. & Markovic, S. N. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transpl. 28, 865\u2013871 (2001).","journal-title":"Bone Marrow Transpl."},{"key":"452_CR12","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/bmt.2017.225","volume":"53","author":"A Kansagra","year":"2018","unstructured":"Kansagra, A. et al. Infusion of autograft natural killer cell\/CD14(+)HLA-DR(DIM) cell ratio predicts survival in lymphoma post autologous stem cell transplantation. Bone Marrow Transpl. 53, 146\u2013154 (2018).","journal-title":"Bone Marrow Transpl."},{"key":"452_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.bbmt.2008.11.028","volume":"15","author":"P Stiff","year":"2009","unstructured":"Stiff, P. et al. Treatment with plerixafor in non-Hodgkin\u2019s lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biol. Blood Marrow Transpl. 15, 249\u2013256 (2009).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"452_CR14","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"SS Neelapu","year":"2017","unstructured":"Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531\u20132544 (2017).","journal-title":"N. Engl. J. Med."},{"key":"452_CR15","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1182\/blood-2013-11-538686","volume":"123","author":"FY Li","year":"2014","unstructured":"Li, F. Y. et al. XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood 123, 2148\u20132152 (2014).","journal-title":"Blood"},{"key":"452_CR16","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1172\/JCI131116","volume":"130","author":"JC Ravell","year":"2020","unstructured":"Ravell, J. C. et al. Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. J. Clin. Investig. 130, 507\u2013522 (2020).","journal-title":"J. Clin. Investig."},{"key":"452_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/MOP.0000000000000156","volume":"26","author":"J Ravell","year":"2014","unstructured":"Ravell, J., Chaigne-Delalande, B. & Lenardo, M. X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection, and neoplasia disease: a combined immune deficiency with magnesium defect. Curr. Opin. Pediatr. 26, 713\u2013719 (2014).","journal-title":"Curr. Opin. Pediatr."},{"key":"452_CR18","doi-asserted-by":"publisher","first-page":"100676","DOI":"10.1016\/j.blre.2020.100676","volume":"44","author":"J Gile","year":"2020","unstructured":"Gile, J., Ruan, G., Abeykoon, J., McMahon, M. M. & Witzig, T. Magnesium: the overlooked electrolyte in blood cancers? Blood Rev. 44, 100676 (2020).","journal-title":"Blood Rev."},{"key":"452_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/10428194.2020.1759056","volume":"61","author":"J Gile","year":"2020","unstructured":"Gile, J. et al. Hypomagnesemia is associated with an increased risk of early clinical failure in patients with Burkitt lymphoma. Leukemia Lymphoma 61, 1\u20133 (2020).","journal-title":"Leukemia Lymphoma"},{"key":"452_CR20","doi-asserted-by":"publisher","first-page":"274","DOI":"10.4103\/0974-7788.76794","volume":"1","author":"MK Goel","year":"2010","unstructured":"Goel, M. K., Khanna, P. & Kishore, J. Understanding survival analysis: Kaplan-Meier estimate. Int. J. Ayurveda Res. 1, 274\u2013278 (2010).","journal-title":"Int. J. Ayurveda Res."},{"key":"452_CR21","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.mayocp.2015.04.023","volume":"90","author":"W Cheungpasitporn","year":"2015","unstructured":"Cheungpasitporn, W., Thongprayoon, C. & Qian, Q. Dysmagnesemia in hospitalized patients: prevalence and prognostic importance. Mayo Clin. Proc. 90, 1001\u20131010 (2015).","journal-title":"Mayo Clin. Proc."},{"key":"452_CR22","doi-asserted-by":"publisher","unstructured":"Ravasco, P. Nutrition in Cancer Patients. J. Clin. Med. https:\/\/doi.org\/10.3390\/jcm8081211 (2019).","DOI":"10.3390\/jcm8081211"},{"key":"452_CR23","doi-asserted-by":"publisher","first-page":"i39","DOI":"10.1093\/ndtplus\/sfr166","volume":"5","author":"J Cunningham","year":"2012","unstructured":"Cunningham, J., Rodr\u00edguez, M. & Messa, P. Magnesium in chronic kidney disease Stages 3 and 4 and in dialysis patients. Clin. Kidney J. 5, i39\u2013i51 (2012).","journal-title":"Clin. Kidney J."},{"key":"452_CR24","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1056\/NEJMoa1900623","volume":"382","author":"JU Peled","year":"2020","unstructured":"Peled, J. U. et al. Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. N. Engl. J. Med. 382, 822\u2013834 (2020).","journal-title":"N. Engl. J. Med."},{"key":"452_CR25","first-page":"101","volume":"52","author":"W Merza","year":"2008","unstructured":"Merza, W., Majid, A., Daoud, M. & Almothaffar, A. Serum magnesium concentration in patients with leukemia and lymphoma. J. Fac. Med. Baghdad 52, 101\u2013104 (2008).","journal-title":"J. Fac. Med. Baghdad"},{"key":"452_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.clml.2011.09.215","volume":"12","author":"LP Chen","year":"2012","unstructured":"Chen, L. P., Lin, S. J. & Yu, M. S. Prognostic value of platelet count in diffuse large B-cell lymphoma. Clin. Lymphoma Myeloma Leuk. 12, 32\u201337 (2012).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"452_CR27","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/ndtplus\/sfr163","volume":"5","author":"W Jahnen-Dechent","year":"2012","unstructured":"Jahnen-Dechent, W. & Ketteler, M. Magnesium basics. Clin. Kidney J. 5, i3\u2013i14 (2012).","journal-title":"Clin. Kidney J."},{"key":"452_CR28","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s00277-014-2031-2","volume":"93","author":"S Dalia","year":"2014","unstructured":"Dalia, S. et al. Serum albumin retains independent prognostic significance in diffuse large B-cell lymphoma in the post-rituximab era. Ann. Hematol. 93, 1305\u20131312 (2014).","journal-title":"Ann. Hematol."},{"key":"452_CR29","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/clinchem\/31.2.244","volume":"31","author":"MH Kroll","year":"1985","unstructured":"Kroll, M. H. & Elin, R. J. Relationships between magnesium and protein concentrations in serum. Clin. Chem. 31, 244\u2013246 (1985).","journal-title":"Clin. Chem."},{"key":"452_CR30","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1038\/sj.ejcn.1601689","volume":"57","author":"M Tam","year":"2003","unstructured":"Tam, M., G\u00f3mez, S., Gonz\u00e1lez-Gross, M. & Marcos, A. Possible roles of magnesium on the immune system. Eur. J. Clin. Nutr. 57, 1193\u20131197 (2003).","journal-title":"Eur. J. Clin. Nutr."},{"key":"452_CR31","doi-asserted-by":"publisher","unstructured":"Kieboom, B. C. et al. Serum magnesium and the risk of death from coronary heart disease and sudden cardiac death. J. Am. Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.115.002707 (2016).","DOI":"10.1161\/jaha.115.002707"},{"key":"452_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0098971","volume":"9","author":"G An","year":"2014","unstructured":"An, G. et al. Association between low serum magnesium level and major adverse cardiac events in patients treated with drug-eluting stents for acute myocardial infarction. PLoS ONE 9, e98971 (2014).","journal-title":"PLoS ONE"},{"key":"452_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2018-000775","volume":"5","author":"JJ DiNicolantonio","year":"2018","unstructured":"DiNicolantonio, J. J., Liu, J. & O\u2019Keefe, J. H. Magnesium for the prevention and treatment of cardiovascular disease. Open Heart 5, e000775 (2018).","journal-title":"Open Heart"},{"key":"452_CR34","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3945\/an.116.012765","volume":"7","author":"RB Costello","year":"2016","unstructured":"Costello, R. B. et al. Perspective: the case for an evidence-based reference interval for serum magnesium: the time has come. Adv. Nutr. 7, 977\u2013993 (2016).","journal-title":"Adv. Nutr."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00452-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T15:42:34Z","timestamp":1669909354000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-021-00452-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,26]]},"references-count":34,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["452"],"URL":"https:\/\/doi.org\/10.1038\/s41408-021-00452-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,26]]},"assertion":[{"value":"26 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"65"}}